Novo Nordisk's Two-Front Battle: A Cardiology Retreat Complicates the GLP-1 Growth Calculus
Published on 09/09/2026 at 13:31 | Editorial boerse-global.de
The Danish pharmaceutical heavyweight finds itself navigating an increasingly bifurcated narrative. Days after securing a politically fortified pricing channel for its blockbuster weight-loss and diabetes drugs in the US, the company has been forced to pull the plug on a second wave of clinical trials in its beleaguered cardiovascular programme.
An independent data monitoring committee has halted two further Phase 3 studies examining Ziltivekimab in heart failure patients, citing a "low probability" that outcomes would diverge from the earlier failed trial. Only a single study, focused on post-heart-attack patients, remains active — with results not expected until the first half of 2027.
The timing could hardly be more awkward. Novo Nordisk is simultaneously touting fresh momentum in its core metabolic franchise, having just launched the oral version of Wegovy in Germany and secured Chinese regulatory review for the same formulation. The juxtaposition crystallises the central tension facing investors: can the commercial engine compensate for a pipeline that keeps shedding its diversification narrative?
The Price of Access
The TrumpRx agreement, which will see semaglutide-based treatments Wegovy and Ozempic offered at $350 per month alongside insulin products NovoLog and Tresiba at $35, represents a calculated trade-off rather than a concession. In exchange for thinner margins per unit, the company locks in a politically shielded distribution channel in its most critical market.
Management's revised full-year guidance, lifted in late August to a range of zero to minus 6 percent growth at constant exchange rates from a prior minus 12 to minus 4 percent, suggests volume expansion is expected to more than offset the pricing give-back. That early release prompted Deutsche Bank to downgrade the stock to Sell — a reminder that conviction in the operational recovery is far from universal.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The German rollout of the Wegovy tablet, which began last Friday, fits the pattern of a company doubling down on its core therapeutic areas. The shares have slipped 3.7 percent since that launch, a move that likely reflects broader market jitters around the name rather than any verdict on the product itself.
A Paediatric Milestone
Amid the pipeline gloom, semaglutide delivered a notable win in a younger demographic. The STEP-Young study met its primary endpoint, with 40.4 percent of children aged six to under twelve no longer classified as obese after 68 weeks of full treatment adherence. The safety profile mirrored that observed in adult and adolescent populations.
The data opens a meaningful expansion of the addressable market, though it arrives with ethical and regulatory questions that are hard to ignore. Prescriptions of GLP-1 medications for children under twelve in the US have surged more than 300-fold since 2019, with Wegovy emerging as the most widely used option. The commercial potential is substantial, but so is the scrutiny.
The Pipeline Question
The repeated Ziltivekimab setbacks carry deeper strategic implications than the pricing debate. Each successive failure erodes the thesis that Novo Nordisk could eventually reduce its reliance on GLP-1 therapies through cardiovascular and inflammatory indications. The company's dependence on a single molecule grows more pronounced with every setback in adjacent therapeutic areas.
The upcoming capital markets day on September 21 will test whether management can articulate a credible pipeline strategy to fill that void. The stakes are considerable: the stock trades at €38.62, roughly 30 percent below its 52-week high of €54.86 reached in January, with technical indicators offering little comfort — an RSI of 42.5 and a price about 6.2 percent beneath its 50-day moving average suggest momentum remains elusive, while elevated volatility points to sustained nervousness.
Competitive Pressures Intensify
The competitive landscape is also shifting. The FDA has granted Eli Lilly's Mounjaro approval for reducing cardiovascular risk in high-risk Type 2 diabetes patients — a differentiation that Novo Nordisk has yet to counter. Should Mounjaro gain traction among prescribers, the gap to the 52-week low of €30.25 could narrow considerably.
The oral Wegovy tablet and the Chinese market entry represent the most tangible catalysts for recapturing share. A breakthrough with patients preferring oral over injectable formulations could generate growth that overshadows the pipeline disappointment, while a Chinese approval — no timeline has been disclosed — would unlock a potentially vast new market.
The calculus for investors is straightforward but unforgiving. The raised guidance and secured US pricing agreements suggest the core semaglutide franchise is more resilient than the share price implies. Yet the third failure in the Ziltivekimab programme underscores how tightly the company's growth narrative is now tied to a single molecule. Until the capital markets day delivers a convincing answer on the pipeline front, market scepticism is likely to persist — regardless of how robust the US sales figures prove to be.
Ad
Novo Nordisk Stock: New Analysis - 9 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
